An attempt to reproduce a previous meta-analysis and a new analysis regarding the impact of directly observed therapy on tuberculosis treatment outcomes.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 15 01 2019
accepted: 02 05 2019
entrez: 24 5 2019
pubmed: 24 5 2019
medline: 30 1 2020
Statut: epublish

Résumé

Directly observed therapy (DOT) is almost universally used for the treatment of TB. Several meta-analyses using different methods have assessed the effectiveness of DOT compared to self-administered therapy (SAT). The results of these meta-analyses often conflict with some concluding DOT is superior and others that there is little or no difference. Meta-analyses can guide policymaking, but such analyses must be reliable. To assess the validity of a previous meta-analysis, we tried to reproduce it. We encountered problems with the previous analysis that did not allow for a meaningful reproduction. We describe the issues we encountered here. We then performed a new meta-analysis comparing the treatment outcomes of adults given treatment with SAT versus DOT. Outcomes in the new analysis are loss to follow-up, treatment failure, cure, treatment completed, and all-cause mortality. All data, documentation, and code used to generate our results is provided. Our new analysis included four randomized and three observational studies with 1603 and 1626 individuals respectively. The pooled relative risks (RR) are as follows: Lost to follow-up (RR = 1.2, 95% CI 0.9, 1.7), Treatment Failure (RR = 1.1, 95% CI 0.6, 2), Cure (RR = 0.9, 95% CI 0.8, 1.1), Treatment Completion (RR = 1, 95% CI 0.9, 1.1), Mortality (RR = 0.9, 95% CI 0.6, 1.3). Based on data from our new meta-analysis, the magnitude of the difference between DOT and SAT for all reported outcomes is small, and none of the differences are statistically significant.

Identifiants

pubmed: 31120965
doi: 10.1371/journal.pone.0217219
pii: PONE-D-19-00551
pmc: PMC6532908
doi:

Substances chimiques

Antitubercular Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0217219

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Clin Infect Dis. 2013 Oct;57(7):1063-4
pubmed: 23811418
Int J Tuberc Lung Dis. 2001 Oct;5(10):912-9
pubmed: 11605884
Int J Tuberc Lung Dis. 2014 Sep;18(9):1092-8
pubmed: 25189558
Control Clin Trials. 1996 Feb;17(1):1-12
pubmed: 8721797
PLoS Med. 2018 Jul 3;15(7):e1002595
pubmed: 29969463
Lancet. 2001 Mar 3;357(9257):664-9
pubmed: 11247549
N Engl J Med. 1995 Jul 27;333(4):229-33
pubmed: 7791840
Int J Tuberc Lung Dis. 2003 Feb;7(2):103-9
pubmed: 12588009
Am J Respir Crit Care Med. 2004 Sep 1;170(5):561-6
pubmed: 15184210
Antimicrob Agents Chemother. 2012 Sep;56(9):4937-44
pubmed: 22802244
J Clin Epidemiol. 2009 Oct;62(10):1006-12
pubmed: 19631508
Clin Infect Dis. 2013 Jul;57(1):21-31
pubmed: 23487389
Trop Med Int Health. 2003 Mar;8(3):204-10
pubmed: 12631309
Int J Tuberc Lung Dis. 2002 Aug;6(8):662-5
pubmed: 12150476
Semin Respir Crit Care Med. 2013 Feb;34(1):3-16
pubmed: 23460002
Int J Tuberc Lung Dis. 2007 Jul;11(7):762-8
pubmed: 17609051
Indian J Med Sci. 2002 Jan;56(1):19-21
pubmed: 12508627
Int J Tuberc Lung Dis. 2000 Jun;4(6):550-4
pubmed: 10864186
Trans R Soc Trop Med Hyg. 1999 Sep-Oct;93(5):552-7
pubmed: 10696421
Int J Tuberc Lung Dis. 1997 Dec;1(6):509-17
pubmed: 9487448
PLoS One. 2008 Aug 28;3(8):e3089
pubmed: 18769479
BMC Med Res Methodol. 2007 Jan 23;7:5
pubmed: 17244367
Science. 2010 Jan 22;327(5964):415-6
pubmed: 20093459
Science. 2011 Dec 2;334(6060):1226-7
pubmed: 22144613
Int J Tuberc Lung Dis. 2013 Jun;17(6):719-27
pubmed: 23541232
Stat Med. 2007 Apr 30;26(9):1964-81
pubmed: 16955539
Trop Med Int Health. 2002 Mar;7(3):271-9
pubmed: 11903990
Cochrane Database Syst Rev. 2007 Oct 17;(4):CD003343
pubmed: 17943789
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
Afr Health Sci. 2002 Apr;2(1):16-23
pubmed: 12789110
Stat Med. 2002 Jun 15;21(11):1575-600
pubmed: 12111921
Res Synth Methods. 2011 Dec;2(4):238-53
pubmed: 26061888
Int J Tuberc Lung Dis. 2004 Oct;8(10):1248-54
pubmed: 15527158
BMC Infect Dis. 2016 Oct 4;16(1):537
pubmed: 27716104
Int J Tuberc Lung Dis. 2003 Sep;7(9):848-54
pubmed: 12971668
Clin Infect Dis. 2013 Oct;57(7):1064-5
pubmed: 23811419
Cochrane Database Syst Rev. 2015 May 29;(5):CD003343
pubmed: 26022367
Lancet. 1998 Oct 24;352(9137):1340-3
pubmed: 9802271
Trop Med Int Health. 2004 May;9(5):559-65
pubmed: 15117299
BMJ. 2003 Oct 11;327(7419):823-4
pubmed: 14551066
J Infect Dis. 2011 Dec 15;204(12):1951-9
pubmed: 22021624
Clin Infect Dis. 2013 Oct;57(7):1062-3
pubmed: 23811420
Int J Tuberc Lung Dis. 2018 Jul 1;22(7):731-740
pubmed: 29914598
Stat Med. 1999 Oct 30;18(20):2693-708
pubmed: 10521860
PLoS Biol. 2015 Jun 09;13(6):e1002165
pubmed: 26057340
Salud Publica Mex. 1998 May-Jun;40(3):272-5
pubmed: 9670789

Auteurs

Brian McKay (B)

Department of Epidemiology and Biostatistics, The University of Georgia, Athens, Georgia, United States of America.

Maria Castellanos (M)

Department of Epidemiology and Biostatistics, The University of Georgia, Athens, Georgia, United States of America.

Mark Ebell (M)

Department of Epidemiology and Biostatistics, The University of Georgia, Athens, Georgia, United States of America.

Christopher C Whalen (CC)

Department of Epidemiology and Biostatistics, The University of Georgia, Athens, Georgia, United States of America.

Andreas Handel (A)

Department of Epidemiology and Biostatistics, The University of Georgia, Athens, Georgia, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH